Old Web
English
Sign In
Acemap
>
authorDetail
>
Wieland D. Müskens
Wieland D. Müskens
Medicine
Biosimilar
Internal medicine
Etanercept
Rheumatology
4
Papers
11
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Effect of significant weight loss on disease activity: reason to implement this non-pharmaceutical intervention in daily clinical practice.
2021
RMD Open
Julia M. Weijers
Wieland D. Müskens
Piet L. C. M. van Riel
Show All
Source
Cite
Save
Citations (1)
Does Etanercept biosimilar prescription in a rheumatology center bend the medication cost curve
2020
The Journal of Rheumatology
Wieland D. Müskens
Sanne A A Rongen-van Dartel
Piet L. C. M. van Riel
Eddy M. M. Adang
Show All
Source
Cite
Save
Citations (1)
One-year results after transitioning from Etanercept Originator to Biosimilar in a shared decision-making promoting setting in rheumatology
2020
Rheumatology Advances in Practice
Wieland D. Müskens
Sanne A A Rongen-van Dartel
Steven Teerenstra
Eddy M. M. Adang
Piet L. C. M. van Riel
Show All
Source
Cite
Save
Citations (6)
Biosimilars in the management of chronic inflammatory diseases: The Dutch experience
2019
Wieland D. Müskens
Sanne A A Rongen-van Dartel
Eddy M. M. Adang
Piet L. C. M. van Riel
Show All
Source
Cite
Save
Citations (3)
1